Indoximod: Phase Ib/II data

Data from 12 evaluable patients with metastatic pancreatic cancer in the Phase Ib portion of an open-label, U.S. Phase Ib/II trial showed that twice-daily oral indoximod plus gemcitabine and Abraxane...